Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

F.M. Speetjens, M.J.P. Welters, M. Slingerland, P.D. van Steenwijk, I.C.F.M. Roozen, S. Boekestijn, N. Loof, G.G. Zom, R. Valentijn, W.J. Krebber, C.J.M. Melief, D.V. Filippov, H. Gelderblom, S.H. van der Burg, F. Ossendorp

Research output: Contribution to journalConference Abstract/Poster in journalAcademic

Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021

Cite this